Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Top Cited Papers
Open Access
- 21 December 2007
- journal article
- research article
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 5 (1), 70
- https://doi.org/10.1186/1477-7525-5-70
Abstract
Understanding what constitutes an important difference on a HRQL measure is critical to its interpretation. The aim of this study was to provide a range of estimates of minimally important differences (MIDs) in EQ-5D scores in cancer and to determine if estimates are comparable in lung cancer.Keywords
This publication has 25 references indexed in Scilit:
- Health Utilities Using the EQ-5D in Studies of CancerPharmacoEconomics, 2007
- Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinomaAnnals of Oncology, 2006
- A Comparison of Clinically Important Differences in Health‐Related Quality of Life for Patients with Chronic Lung Disease, Asthma, or Heart DiseaseHealth Services Research, 2005
- US Valuation of the EQ-5D Health StatesMedical Care, 2005
- A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scaleJournal of Clinical Epidemiology, 2004
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire?Results from Eastern Cooperative Oncology Group (ECOG) Study 5592Journal of Clinical Epidemiology, 2002
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- Quality of life evaluation in oncological clinical trials — the EORTC modelEuropean Journal Of Cancer, 2000
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993